Cryoport (CYRX) Q2 FY26 earnings call

Cryoport delivered robust Q2 FY26 results, driven by strong growth in its Life Science Services segment and the achievement of positive adjusted EBITDA, marking a key milestone in its profitability pathway. The company reaffirmed its full-year revenue guidance, balancing strong operational performance with ongoing macroeconomic uncertainties, while continuing to expand its global infrastructure and leverage AI for efficiency.